Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-control…

Overview of attention for article published in Annals of the Rheumatic Diseases, January 2013

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

patent: 52 patents

Citations

dimensions_citation: 308 Dimensions

Readers on

mendeley: 243 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 52 patents that reference this research output.

Compound targeting IL-23A and TNF-alpha and uses thereof

Grant US-11680096-B2

United States of America

Anti-IL-23 antibodies

Grant US-11078265-B2

United States of America

Polynucleotides encoding immune modulating polypeptides

Grant US-10815291-B2

United States of America

Compound targeting IL-23A and TNF-alpha and uses thereof

Grant US-10793629-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 48 additional patents.